MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2017

Jan 10, 2017

ASX Announcement

==> picture [117 x 45] intentionally omitted <==

MAYNE PHARMA LAUNCHES FABIOR[®] AND SORILUX[®] IN THE UNITED STATES

11 January 2017, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commencement of promotion of Fabior® (tazarotene) Foam, 0.1% and Sorilux® (calcipotriene) Foam, 0.005% in the United States by Mayne Pharma’s Specialty Brands division.

These foam products previously marketed by GlaxoSmithKline (GSK), were acquired by Mayne Pharma in August 2016 and are complementary dermatology products to Doryx®, the first branded product launched by Mayne Pharma’s Specialty Brands division in the United States in May 2015.

Fabior is a patent-protected foam product indicated for the topical treatment of acne, the most prevalent skin disease in the United States affecting as many as 50 million people of all ages[1] . Fabior is part of the single active retinoid market in which 5 million prescriptions are written per annum. This market is significantly larger than the oral antibiotic acne market that Doryx participates in as topical products are used more frequently by acne patients across the disease spectrum ranging from mild and moderate to severe acne cases.

Sorilux is a patent-protected foam product indicated for the topical treatment of plaque psoriasis of the scalp and body affecting up to 6 million Americans each year[1] . Sorilux is part of the single active Vitamin D market in which 0.5 million prescriptions are written per annum.

Mayne Pharma’s CEO Scott Richards said, “Both Fabior and Sorilux are a great strategic fit with the existing Doryx franchise and participate in attractive and growing markets. Both products are well differentiated with compelling clinical data that physicians and patients will appreciate. The foam delivery platform has a well-established reputation with dermatologists due to ease of application, especially in hair-bearing areas and under clothing. With a focused and sustained marketing effort, we can further support the needs of patients and dermatologists and these products will become important treatment options for people with acne and plaque psoriasis.”

“We have met our planned commercial launch timing and have also now internalised our 60person dermatology sales team from a third party contract sales organisation, which is expected to provide cost savings, improved ability to attract and retain talent, improved performance management and ultimately improved sales force effectiveness. Over time we expect to commercialise complementary product innovations in dermatology and other specialty therapeutic areas utilising the Company’s internal pipeline or via targeted in-licensing and/or product acquisitions.”

For further information contact:

Scott Richards +61 8 8209 2410 Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

1 American Academy of Dermatology

==> picture [125 x 126] intentionally omitted <==

Page 1

==> picture [117 x 45] intentionally omitted <==

ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.

About Fabior ®

Fabior is a retinoid in a topical foam formulation for the treatment of acne vulgaris in patients 12 years of age and older. Fabior foam is not for oral, ophthalmic, or intravaginal use . Full prescribing information for Fabior is available here.

About Sorilux ®

Sorilux foam contains calcipotriene, a synthetic vitamin D3 analogue. It is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients aged 18 years and older. Plaque psoriasis is a chronic, noncontagious, inflammatory skin condition that appears as red patches covered with silvery flakes often found on the elbows, scalp and knees but can also affect other parts of the body. Full prescribing information for Sorilux is available here.

==> picture [125 x 126] intentionally omitted <==

Page 2